Cognition Therapeutics Reports First Quarter Financial Update 2025
Cognition Therapeutics Announces Financial Results and Business Update
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease -
- Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC -
- Two posters at ARVO highlight zervimesine's role in supporting retinal cell health -
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders, has released its financial results for the first quarter of 2025, alongside a comprehensive business update.
“In our pursuit of advancing treatments for Alzheimer's disease and dementia with Lewy bodies (DLB), our first quarter proved to be a productive period,” commented Lisa Ricciardi, president and CEO of Cognition Therapeutics. “We have formally requested the U.S. Food and Drug Administration (FDA) schedule an end-of-Phase 2 (EOP2) meeting to discuss the findings from the SHINE study in Alzheimer’s and the subsequent steps toward a registrational study. Additionally, we are in the process of securing a commercial investigational new drug (IND) application for our lead candidate, zervimesine (CT1812), in DLB, which is a significant step forward.”
Key Business and Corporate Highlights
The company's recent updates reflect its commitment to research and development:
- Requested an EOP2 meeting with the FDA to discuss the SHINE study outcomes in Alzheimer’s disease.
- Results from the Phase 2 SHIMMER study on DLB are set to be presented at the upcoming Alzheimer’s Association International Congress (AAIC).
- Two posters will be showcased at the Association for Research in Vision and Ophthalmology (ARVO) meeting, detailing how zervimesine regulates lipid metabolism and safeguards retinal cells from damage.
- Earlier in the year, data from the SHIMMER study was prominently featured at the International Lewy Body Dementia Conference, emphasizing its significance in the field.
First Quarter Financial Analysis
As of March 31, 2025, Cognition Therapeutics reported cash and cash equivalents amounting to approximately $16.4 million. The total grant funds from the National Institute of Aging stood at $47.0 million, ensuring a robust cash runway to sustain operations into the latter part of 2025.
Looking at the expenses, research and development costs for the quarter were $10.8 million, reflecting a slight increase from the previous year's $10.6 million. This increase was attributed to the ramp-up in Phase 2 trial activities.
On the administrative side, expenses were recorded at $3.0 million, a decrease from last year’s $3.5 million, primarily due to lower stock compensation costs, though there was an uptick in professional fees.
Net loss for the quarter was reported at $8.5 million, representing a decrease in loss per share from $(0.27) in 2024 to $(0.14) in 2025, indicating a positive trajectory in financial performance despite the losses.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is dedicated to discovering and developing small molecule therapeutics targeting age-related neurodegenerative disorders. The company is currently innovating with zervimesine (CT1812) within clinical programs that address Alzheimer’s disease and DLB. These therapies aim to modify the disease mechanism through interaction with the sigma-2 receptor, thereby differentiating from existing treatment modalities.
For more information, visit Cognition Therapeutics.
Frequently Asked Questions
What financial results did Cognition Therapeutics report for Q1 2025?
Cognition reported a net loss of $8.5 million, with cash reserves of approximately $16.4 million as of March 31, 2025.
What upcoming presentations is Cognition Therapeutics participating in?
The company will present findings at the Alzheimer’s Association International Congress (AAIC) and showcase two posters at the ARVO meeting.
What is the status of their Alzheimer’s and DLB studies?
Cognition has requested an EOP2 meeting with the FDA regarding its Alzheimer’s study and initiated IND applications for zervimesine in DLB.
How does zervimesine aim to help patients?
Zervimesine is being developed to regulate pathways impaired in neurodegenerative diseases, providing a new mechanism of action distinct from other treatments.
Who can I contact for more information about Cognition Therapeutics?
For inquiries, you can reach Cognition Therapeutics at info@cogrx.com.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.